Franklin V. Peale

Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor.

Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis.

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma.

Magnetic resonance angiography reveals therapeutic enlargement of collateral vessels induced by VEGF in a murine model of peripheral arterial disease.

Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.

Bv8 regulates myeloid-cell-dependent tumour angiogenesis.

Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.

Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease.

Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis.

Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.

Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.

Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis.

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Monitoring and Targeting Anti-VEGF Induced Hypoxia within the Viable Tumor by F-MRI and Multispectral Analysis.

Synthetic Antigen Gels as Practical Controls for Standardized and Quantitative Immunohistochemistry.

BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.

Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.